Replies to post #117769 on Biotech Values

[DewDiligence]

Not all patients just those with CC genotype.

Understood. I just don’t think IL28B is a strong enough biomarker to legitimately use it in the way that was suggested in the editorial you cited.

I do think that IL28B status should be used but the other way around: not treat patients who will likely not respond to interferon.

Are you referring to the first-line setting?

[DewDiligence]

VRTX will conduct a Telaprevir+SoC trial in CC-variant IL28B patients that consists of only three months of total treatment (http://finance.yahoo.com/news/Vertex-Reports-First-Quarter-bw-1531348977.html?x=0&.v=1 ).

This sounds like a good way to further differentiate Telaprevir from Boceprevir.